Gilteritinib

Known as: 6-Ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)pyrazine-2-carboxamide 
An orally bioavailable inhibitor of the receptor tyrosine kinases (RTKs) FMS-related tyrosine kinase 3 (FLT3, STK1, or FLK2), AXL (UFO or JTK11) and… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2017-2017
051020172017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Acute myeloid leukemia (AML) is a heterogeneous disease with cure rates of only 30-40% in patients <60 years old. Cytogenetic and… (More)
Is this relevant?
2018
2018
Controversy exists whether internal tandem duplication of FMS-like tyrosine kinase 3 (FLT3-ITD) allelic ratio (AR) and/or length… (More)
Is this relevant?
2017
2017
BACKGROUND Internal tandem duplication mutations in FLT3 are common in acute myeloid leukaemia and are associated with rapid… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2017
2017
Advances in the understanding of the molecular basis for acute myeloid leukemia (AML) have generated new potential targets for… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2017
2017
  • Cancer discovery
  • 2017
Gilteritinib was well tolerated in a phase I/II dose-escalation and dose-expansion study. 
Is this relevant?
Review
2017
Review
2017
FLT3 mutations are present in about one-third of patients with acute myeloid leukemia (AML). Several FLT3 inhibitors have been… (More)
  • table 1
Is this relevant?
Review
2017
Review
2017
FMS-like tyrosine kinase 3 (FLT3) is one of the most commonly mutated genes in AML. FLT3 is mutated in ~30% of patients with AML… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
2017
2017
  • The Lancet. Oncology
  • 2017
Perl AE, Altman JK, Cortes J, et al. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid… (More)
Is this relevant?
2017
2017
  • The Lancet. Oncology
  • 2017
Perl AE, Altman JK, Cortes J, et al. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid… (More)
Is this relevant?